Background: Gliomas are the most common form of malignant primary brain tumors in adults with an annual incidence of approximately five per 100,000 people. In Egypt, primary Central Nervous System (CNS) neoplasms are rare, constituting about 1-2% of all human neoplasms, with High Grade Gliomas (HGGs) being the most common type. The study aims to discover the histo-pathological aspect of HGGs, risk factors, and descriptive analysis of treatment received in Clinical oncology department affiliated with Alexandria University Hospital. Methods: Data were collected and analyzed for four hundred and thirty four patients with histologically proven HGGs in the period between 2003 and 2012. Results: Age of patients ranged from 21 to 83 years. Most cases (80.4%) were Glioblastoma Multiform (GBM), followed by Anaplastic Astrocytoma (AA) reaching14.3% of patients. In this study, 45.4% of patients had karnofsky performance score (KPS) more than 60%. Only 2.5% of patients underwent gross total resection (GTR), 25.6% underwent Subtotal Resection (STR) and 50% of patients underwent excisional biopsy. Patients received radiotherapy were 355 about 81.8% of patients with HGGs (80.2% of them received Radiotherapy (RT) only, 11.8% received RT followed by Adjuvant Chemotherapy (ACT), 4% received Concomitant Chemoradiotherapy (CCRT) and 4% received CCRT followed by ACT), 16.6% of patients received only best supportive care (BSC) and 2.3% did not receive treatment. The median Overall Survival (OS) was 10, 13, 19 and 15 months for patients received RT only, CCRT, CCRT followed by ACT and RT followed by ACT, respectively. Conclusion: Delayed presentation and inadequate GTR together with unavailability of TMZ could affect outcome in limited resource countries.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.